Peptidomimetic blockade of MYB in acute myeloid leukemia
MYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-02618-6 |
id |
doaj-a470abd9ea4643cfb47136bbe875cfb7 |
---|---|
record_format |
Article |
spelling |
doaj-a470abd9ea4643cfb47136bbe875cfb72021-05-11T10:06:53ZengNature Publishing GroupNature Communications2041-17232018-01-019111310.1038/s41467-017-02618-6Peptidomimetic blockade of MYB in acute myeloid leukemiaKavitha Ramaswamy0Lauren Forbes1Gerard Minuesa2Tatyana Gindin3Fiona Brown4Michael G. Kharas5Andrei V. Krivtsov6Scott A. Armstrong7Eric Still8Elisa de Stanchina9Birgit Knoechel10Richard Koche11Alex Kentsis12Molecular Pharmacology Program, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteDepartment of Pathology and Cell Biology, Columbia University Medical Center and New York Presbyterian HospitalMolecular Pharmacology Program, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteCenter for Epigenetics Research, Sloan Kettering InstituteDepartment of Pediatrics, Memorial Sloan Kettering Cancer CenterMolecular Pharmacology Program, Sloan Kettering InstituteAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer CenterDepartment of Pediatric Oncology, Dana-Farber Cancer InstituteCenter for Epigenetics Research, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteMYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.https://doi.org/10.1038/s41467-017-02618-6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kavitha Ramaswamy Lauren Forbes Gerard Minuesa Tatyana Gindin Fiona Brown Michael G. Kharas Andrei V. Krivtsov Scott A. Armstrong Eric Still Elisa de Stanchina Birgit Knoechel Richard Koche Alex Kentsis |
spellingShingle |
Kavitha Ramaswamy Lauren Forbes Gerard Minuesa Tatyana Gindin Fiona Brown Michael G. Kharas Andrei V. Krivtsov Scott A. Armstrong Eric Still Elisa de Stanchina Birgit Knoechel Richard Koche Alex Kentsis Peptidomimetic blockade of MYB in acute myeloid leukemia Nature Communications |
author_facet |
Kavitha Ramaswamy Lauren Forbes Gerard Minuesa Tatyana Gindin Fiona Brown Michael G. Kharas Andrei V. Krivtsov Scott A. Armstrong Eric Still Elisa de Stanchina Birgit Knoechel Richard Koche Alex Kentsis |
author_sort |
Kavitha Ramaswamy |
title |
Peptidomimetic blockade of MYB in acute myeloid leukemia |
title_short |
Peptidomimetic blockade of MYB in acute myeloid leukemia |
title_full |
Peptidomimetic blockade of MYB in acute myeloid leukemia |
title_fullStr |
Peptidomimetic blockade of MYB in acute myeloid leukemia |
title_full_unstemmed |
Peptidomimetic blockade of MYB in acute myeloid leukemia |
title_sort |
peptidomimetic blockade of myb in acute myeloid leukemia |
publisher |
Nature Publishing Group |
series |
Nature Communications |
issn |
2041-1723 |
publishDate |
2018-01-01 |
description |
MYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth. |
url |
https://doi.org/10.1038/s41467-017-02618-6 |
work_keys_str_mv |
AT kavitharamaswamy peptidomimeticblockadeofmybinacutemyeloidleukemia AT laurenforbes peptidomimeticblockadeofmybinacutemyeloidleukemia AT gerardminuesa peptidomimeticblockadeofmybinacutemyeloidleukemia AT tatyanagindin peptidomimeticblockadeofmybinacutemyeloidleukemia AT fionabrown peptidomimeticblockadeofmybinacutemyeloidleukemia AT michaelgkharas peptidomimeticblockadeofmybinacutemyeloidleukemia AT andreivkrivtsov peptidomimeticblockadeofmybinacutemyeloidleukemia AT scottaarmstrong peptidomimeticblockadeofmybinacutemyeloidleukemia AT ericstill peptidomimeticblockadeofmybinacutemyeloidleukemia AT elisadestanchina peptidomimeticblockadeofmybinacutemyeloidleukemia AT birgitknoechel peptidomimeticblockadeofmybinacutemyeloidleukemia AT richardkoche peptidomimeticblockadeofmybinacutemyeloidleukemia AT alexkentsis peptidomimeticblockadeofmybinacutemyeloidleukemia |
_version_ |
1721448752860889088 |